Please type a plus sign (+) inside this box →

/PTO/SB/21 (08-00)

Approved for use through 10/31/2002 OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE squired to respond to a collection of information unless it a scrays a valid CMB control number.

TRANSMITTAL **FORM**

(To be used for all correspondence after initial filing)

5-5-6-46-6-6-6-6-6-6-6-6-6-6-6-6-6-6-6-6	of the contract of the contrac	
Application Number	10/050,054	
Filing Date	January 16, 2002	RECEIVED
First Named Inventor	Emad S. Alnemri	
Group Art Unit	1646	DEC 0 5 2002
Examiner Name		TECH CENTER 1600, 2900
Attorney Docket No.	480140.474	1500,530(

ENCLOSURES (check all that apply)								
Fee Transmittal Form Fee Attached Amendment/Response After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement, Forms PTO-1449 (4 Sheets) Cited References (41) Certified Copy of Priority Document(s) Response to Missing Parts under 37 C.F.R. 1.52 or 1.53 Response to Missing Parts/Incomplete Application Response to Missing Parts/Incomplete Application Response to Missing Parts/Incomplete Application Fee Attached Assignment Papers (for an Application) Drawing(s) After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Petition Petition Power of Attorney. Revocation, Change of Correspondence Address Declaration Statement under 37 CFR 3.73(b) Terminal Disclaimer Small Entity Statement Request for Refund Response to Missing Parts/Incomplete Application Remarks								
	ATURE OF APPLICANT, ATTORNEY,	OR AGENT						
	T. Christiansen, Ph.D. b. 44.614	00500 PATENT TRADEMARK OFFICE						
Signature	- 1,000							
Date Novemb	er 26, 2002							
CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents. Washington, D.C. 20231 on the date specified below.								
Typed or printed name Larry Dobson								
Signature Date: November 26, 2002								





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Applicants

Emad S. Alnemri

DEC 0 5 2002

Application No.

10/050,054

TECH CENTER 1600/2900

Filed

January 16, 2002

For

INHIBITION OF INTERLEUKIN-1-β SECRETION BY CARD

PROTEINS

Art Unit

: 1646

Docket No.

: 480140.474

Date

: November 26, 2002

Commissioner for Patents Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicant wishes to make known to the Patent and Trademark Office the references set forth on the attached form PTO-1449 (copies of the cited references are enclosed).

As to any reference supplied, applicant does not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserves the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicant's duty to disclose all information he is aware of which is believed relevant to the examination of the above-identified application, applicant believes that his invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted.

Emad S. Alnemri

Seed Intellectual Property Law Group PLLC

William T. Christiansen, Ph.D.

Registration No. 44,614

WTC:ljd

Enclosures:

Postcard Form PTO/SB/21 Forms PTO-1449 (4 Sheets) Cited References (41)

701 Fifth Avenue, Suite 6300 Seattle, Washington 98104-7092

Phone: (206) 622-4900 Fax: (206) 682-6031

D. NrPortbl\(\)Manage LARRYD\(\)337199_1 DOC

		CONTRACTOR OF THE PROPERTY OF					Sheet	. <u>2</u> of <u>4</u>	
FORM P1O-1 (REV 7-80)	449	US DEPARTMENT OF COMM PATENT AND TRADEMARK O		1		APPLICATIO 10/050.0	on No		
IN	FOR:	NEW N. DISCLOSURE STATEMENT		APPLICANT Emad S. Alnemri	-				
		(Use several sheets if necessary)		January 16, 2002		GROUP ART	GROUP ART UNIT		
		U.S. PATE	ENT	DOCUMENTS					
"I X AMINER INITIAL		DOCUMENT NUMBER DATE		NAME	ČLASS	SUBCLASS	EILING IL APPRO		
	BA								
		FOREIGN PA	ATEN	NT DOCUMENTS	RECE	IVED)		
		DOCUMENT NUMBER DATE		COUNTRY	DEC (5 7052	TRANSI		
				TE	CH CENTE	H 1600/290	O YES	NO NO	
	BB								
		OTHER PRIOR ART tine			·	DD / () + D I			
	BC	Chou et al., "Solution structure of interaction in caspase-2 and caspas							
		Druilhe et al "Regulation of IL-1,						 nant	
	negative caspase recruitment domain proteins." Cell Death and Differentiation 8(6):649-657.								
		June 2001.			D (M - 41)	1 1 CC			
	BE	Eberstadt et al., "NMR structure ar domain," <i>Nature 392</i> (6679):941-9			D (Morti)	death-effe	ctor		
	BF	Guiet and Vito, "Caspase recruitm	ent c	lomain (CARD)-depen					
	DI	mediate bcl1()-induced NF-κB acti							
	BG	Hofmann, "The modular nature of 9):1113-1128, July 1999.	гаро	ptotic signaling proteir	is, C <i>ell. A</i>	Mol. Lije Se	21. 33(8	-	
	DU	Hofmann et al., "The CARD doma	ain: a	new apoptotic signall	ing motif."	Trends Bi	ochem.	Sci.	
	BH	22(5):155-156. May 1997.				·		•	
		Howard et al., "IL-1-converting en IL-1 β precursor at two distinct site						he	
	BI	147(9):2964-2969, November 1, 19	es an 991.	id does not cleave 31-k	Da IIIW	. J. Immu	101.		
		Humke et al., "ICEBERG: a novel		bitor of interleukin-1β	generation	n," Cell 10.	3(1):99	_	
	BJ	111, September 29, 2000.							
	BL.		Lee et al., "Cop, a caspase recruitment domain-containing protein and inhibitor of caspase-1 activation processing," <i>J. Biol. Chem.</i> 276(37):34495-34500, September 14, 2001.						
		Li et al., "Cytochrome c and dATP					olex		
	ВМ	initiates an apoptotic protease cascade," <i>Cell 91</i> (4):479-489, November 14, 1997.							
	BN	MacFarlane et al., "Identification a							
		cytotoxic ligand TRAIL," J. Biol. Chem. 272(41):25417-25420, October 10, 1997.							
EVAND	BO								
EXAMIN	EK			DATE CONSIDERED					
* EXAMIN	NER:	Initial if reference considered, whether or not criteria is	n con	nformance with MPFP 609 Draw	line through ci	tation if not in		_	

conformance and not considered. Include copy of this form with next communication to applicant(s)

·		KPE'S			4		.* *		
		0, 3						Sheet 1 of 4	
FORM P1O-1 (REV 7-80)	449	267. 0	S DEPARTMENT TENT AND TRAD		480140,474		10/050,0		
IN	FOR	MATROMANISCLOSUI	RE STATEM	ENT	APPLICANT Emad S. Alnemri		····		
		(Use several sheets if nec	essarv)		January 16, 2002		GROUP ART	UNII	
			U.S.	. PATENT I	DOCUMENTS				
*EXAMINER INITIAL		DOCUMENT NUMBER DATE		NAME:	CLASS	SUBCLASS	ERESCOALE IE APPPOSRIATE		
	AA								
ı,			FOREI	GN PATEN	NT DOCUMENTS				
		DOCUMENT NUMBER	DATE		COUNTRY			TRANSLATION YES NO	
	AB	EP 1 033 401 A2	09/06/00	EPO			DE		•
	ΛC	WO 01/90156	11/29/01	WIPO				CEIVED	J
"		ОТНЕ	R PRIOR A	RT (Including	Author, Title, Date, Pertinent I	ages_Etc)	D	EC 0 5 7002	
	AD				No. AA070591, Octob		TECH (DENTER 1600/290)()
	ΑE	Genbank Accession No. AA046000, September 6, 1996.							
	AF	Genbank Accession No. AA070591, October 27, 1997.							
	AG	Genbank Accession No. AC023068, March 3, 2000.							
	ΑН	Genbank Accession No. AC027011. April 27, 2000.							
	Αl	Genbank Access	ion No. AP	001153, M	arch 22, 2001.				
	ΑJ	Genbank Access	ion No. AP	002787, Ju	ly 13, 2000.				
	AK	Genbank Access	ion No. XP	_005312, 0	October 16, 2001.	-			
	Al.	Genbank Accession No. XP_040782, October 16, 2001.							
	AM	Genbank Accession No. XP_055386, October 16, 2001.							
-	AN	Genbank Accession No. XP 055388, October 16, 2001.							
	ΑO	Geneseq 'Online	Geneseq 'Online! Database, Accession No. AAG01331, September 6, 2000.						
	AΡ	Ahmad et al., "CRADD, a novel human apoptotic adaptor molecule for caspase-2, and FasL/tumor necrosis factor receptor-interacting protein RIP," <i>Cancer Res.</i> 57(4):615-619, February 14, 1997.							
	AQ	Alnemri et al. "Cloning and expression of four novel isoforms of human interleukin-1 B							
EXAMIN	IER				DATE CONSIDERED)			
* EXAMI	NER:				formance with MPEP 609 Dra ith next communication to appl		itation if not in		

	/	0 6 5	_			Sheet 3 of 4		
FORM PTO-1449 COMMERCE PATENT AND TRADEMARK OFFICE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT			ALLY DOCKEL NO APPLICATION NO 480140.474 10/050.054					
			APPLICANT Emad S. Alnemri		- • • • • • • • • • • • • • • • • • • •			
		(Raped) all sheets it necessary)	Filing Date January 16, 2002		GROUP ART	USH		
		U.S. PATENT	DOCUMENTS			-		
*FXAMINER INTHAL		DOCUMENT NUMBER DATE	NAME	ČLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
	CA		F	RECE	IVED			
		FOREIGN PATE	ENT DOCUMENTS	DEC 0	5 2002			
		DOCUMENT NUMBER DATE	COUNTRY		R 1600/290	TRANSLATION VES NO		
	СВ		156	, II OENTE	1 1000/230			
		OTHER PRIOR ART (Including	re Author, Tule, Date, Perunent Pa	ges Etc.)		L		
		Mao et al., "Activation of caspase-1 i			elocation o			
	cc	caspase-1 mediated by its prodomain,	-			1 pro-		
		September 11, 1998.						
		Miura et al., "Induction of apoptosis i	n fibroblasts by IL-1 β-c	converting	g enzyme, a			
	CD		s cell death gene <i>ced-</i> 3.	ell death gene <i>ced-3</i> ," <i>Cell</i> 75(4):653-660.				
		November 19, 1993.						
	CE	Muzio et al., "An induced proximity i	nodel for caspase-8 acti-	vation," J.	Biol. Cher	11.		
		273(5):2926-2930. January 30. 1998.	1.4	· 1	1: 10 (H	10)		
	CF	Nett-Fiordalisi et al., "Characterization Converting Enzyme," <i>J. Cell Biochen</i>		ine Interie	ukin-13 (II	-1β)		
	_	Salvesen and Dixit, "Caspase activation		tv model "	Proc Nat	l Acad		
	CG	Sci. USA. 96(20):10964-10967, Sept		ty model.	7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	r. Hette.		
		Siegel et al., "Death-effector filament		actures tha	it recruit ca	spases and		
	CH	trigger apoptosis," J. Cell Biol. 141(5):1243-1253. June 1, 19 ^o	98.				
	CI	Sleath et al., "Substrate Specificity or		sses Huma	an Interleul	$\sin -1 \beta$." J .		
	-	Biol. Chem. 256:14526-14528, Augus						
	CJ	Srinivasula et al., "Autoactivation of p	procaspase-9 by Apaf-1-	mediated	oligomeriz	ation,"		
-	_	Mol. Cell. 1(7):949-957, June 1998.	maga maamuitusant dansais					
	CK		se recruitment domain-containing protein in the tumor tes NF-κB activation and apoptosis," J. Biol. Chem.					
		274(25):17946-17954, June 18, 1999.	nates Inf-kD activation a	ана арорк)818. J. DIC	n. Chem.		
		Thome et al., "Identification of CARI		that assoc	iates with o	easpase-1 "		
	Cl.	Curr. Biol. 8(15):885-888, July 16, 1998.						
	СМ	Thornberry et al., "A novel heterodim	eric cysteine protease is	required f	or interleul	$kin-1 \beta$		
_		processing in monocytes," Nature 356	6(6372):768-774, April 3	80, 1992.				
	CN							
EXAMIN	ER		DATE CONSIDERED					
* EXAMIN	VER:	Initial if reference considered, whether or not criteria is in c			tation if not in			
		conformance and not considered. Include copy of this form	with next communication to applic	ant(s)				

FORM PTO 1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			(APPLICATION NO 10/050.054				
INFORMATION DISCLOSURE STATEMENT			APPLICANT Emad S. Alnemri					
(Use several sheets if necessary)				FILING DATE January 16, 2002		GROUP ART	iroup art unii 1646	
			U.S. PATENT	DOCUMENTS				
*FXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME.	CLASS	SUBCLASS	HEING DATE IF APPROPRIATE	
	DA							
	DB				F	RECE	IVED 5-2002 R-1600/2900	
	DC.					DEC 0	5 2002	
	DD				TE	TH CENTE	R 1600/2900	
	DE				16	J(10=111-		
			FOREIGN PATE	NT DOCUMENTS				
		DOCUMENT NUMBER	DATE	COUNTRY			TRANSLATION YES NO	
	DF							
	DG							
	ьн							
	ы							
	DJ							
		ОТНЕЯ	R PRIOR ART (Including	z Author, Title, Date, Pertinent Po	iges, Etc.)			
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) Walker et al., "Crystal structure of the cysteine protease interleukin-1β-converting enzyme: a							enzyme: a	
	(p20/p10) ₂ homodimer," <i>Cell 78</i> (2):343-352, July 29, 1994. Wilson et al., "Structure and mechanism of interleukin-1β converting enzyme." <i>Nature</i>							
	370(6487):270-275, July 28, 1994. Yuan et al., "The C. elegans cell death gene ced-3 encodes a protein similar to mammalian							
	DM	interleukin-1 β-co	onverting enzyme," (<i>Cell 75</i> (4):641-652, Nov	vember 19.	1993.		
	DN							
	1)()							
	DP							
	DQ							
	DR						j	
EXAMIN	IER			DATE CONSIDERED				
* EXAMI	NER:			Informance with MPFP 609 Dray with next communication to applic		ation if not in		